Publication:
Recurrence rate of hirsutism after 3 different antiandrogen therapies

dc.contributor.authorsYücelten, D.; Erenus, M.; Gürbüz, O.; Durmuşoğlu, F.
dc.date.accessioned2022-03-15T11:23:16Z
dc.date.accessioned2026-01-10T19:48:42Z
dc.date.available2022-03-15T11:23:16Z
dc.date.issued1999
dc.description.abstractBACKGROUND: Although antiandrogens are frequently and successfully used to treat hirsutism, little attention has been paid to optimal duration of treatment and recurrence rate after cessation of therapy. OBJECTIVE: Our purpose was to determine the recurrence rate of hirsutism after 3 different antiandrogen therapies. METHODS: Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day. Hirsutism scores according to the Ferriman-Gallwey scoring system and endocrine parameters were evaluated before, during, and 1 year after withdrawal of treatment regimens. RESULTS: Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups. However, 1 year after withdrawal of treatment in all antiandrogen therapy groups, hirsutism returned. CONCLUSION: Antiandrogens are effective in the treatment of hirsutism. However, cessation of antiandrogen therapy is followed by recurrence.
dc.identifier.doi10.1016/s0190-9622(99)70408-1
dc.identifier.issn0190-9622
dc.identifier.pubmedPMID: 10411413
dc.identifier.urihttps://hdl.handle.net/11424/249941
dc.language.isoeng
dc.relation.ispartofJournal of the American Academy of Dermatology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFemale
dc.subjectHumans
dc.subjectRecurrence
dc.subjectLuteinizing Hormone
dc.subjectHirsutism
dc.subjectSpironolactone
dc.subjectTestosterone
dc.subjectAndrogen Antagonists
dc.subjectContraceptives, Oral
dc.subjectCyproterone
dc.subjectFlutamide
dc.titleRecurrence rate of hirsutism after 3 different antiandrogen therapies
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage68
oaire.citation.startPage64
oaire.citation.titleJournal of the American Academy of Dermatology
oaire.citation.volume1

Files